Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at μ- and δ-Opioid Receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 2, 2004, Pages 547-554

  Thompson, Chad M ^a   Wojno, Heidi ^a   Greiner, Elisabeth ^b   May, Everette L ^a   Rice, Kenner C ^b   Selley, Dana E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; CYTOCHROME P450; DELTA OPIATE RECEPTOR; DIHYDROCODEINE; DIHYDROMORPHINE; DRUG DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HYDROCODONE; HYDROMORPHONE; MORPHINE; MORPHINE DERIVATIVE; MU OPIATE RECEPTOR; NALOXONE; NARCOTIC AGENT; NORDIHYDROCODEINE; NORHYDROCODONE; NORHYDROMORPHINE; NORMORPHINE; NOROXYCODONE; NOROXYMORPHONE; OXYCODONE; OXYMORPHONE; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CHEMISTRY; CHO CELL; CONTROLLED STUDY; DEMETHYLATION; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; HAMSTER; HUMAN; IN VIVO STUDY; MALE; METABOLISM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHO CELLS; CODEINE; CRICETINAE; FEMALE; GTP-BINDING PROTEINS; HUMANS; MALE; MORPHINE; MORPHINE DERIVATIVES; NARCOTICS; RATS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1642457241     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.058602     Document Type: Article

References (41)

1. Abdelhamid EE, Sultana M, Portoghese PS, and Takemori AE (1991) Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 258:299-303.
2. Asano T and Ross EM (1984) Catecholamine-stimulated guanosine 5′-O-(3-thiotriphosphate) binding to the stimulatory GTP-binding protein of adenylyl cyclase: kinetic analysis in reconstituted phospholipid vesicles. Biochemistry 23:5467-5471.
3. Caraco Y, Tateishi T, Guengerich FP, and Wood AJ (1996) Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. Drug Metab Dispos 24:761-764.
4. Chen ZR, Irvine RJ, Somogyi AA, and Bochner F (1991) Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 48:2165-2171.
5. Cheng CY, Hsin L, Lin Y, Tao P, and Jong T (1996) N-Cubylmethyl substituted morphinoids as novel narcotic antagonists. Bioorg Med Chem 4:73-80.
6. Cleary J, Mikus G, Somogyi A, and Bochner F (1994) The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. J Pharmacol Exp Ther 271:1528-1534.
7. Currie AC, Newbold GT, and Spring FS (1961) 14-Hydroxynorcodeine and its derivatives. J Chem Soc Perkin Trans I:4693-4700.
8. Dayer P, Desmeules J, Leemann T, and Striberni R (1988) Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun 152:411-416.
9. Garadnay S, Herezegh S, Makleit T, Friedmann P, Riba P, and Fürst S (2001) Reactions of morphine derivatives with phenyliodo(III)diacetate (PIDA): synthesis of new morphine analogs. Curr Med Chem 8:621-626.
10. Gettys TW, Sheriff-Carter K, Moomaw J, Taylor IL, and Raymond JR (1994) Characterization and use of crude α-subunit preparations for quantitative immunoblotting of G-proteins. Anal Biochem 220:82-91.
11. Heiskanen T, Olkkola KT, and Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokineties and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64:603-611.
12. Herkenham M and Pert CB (1982) Light microscopic localization of brain opiate receptors: a general autoradiographic method which preserves tissue quality. J Neurosci 2:1129-1149.
13. 5]enkephalin. Eur J Pharmacol 165:1-10.
14. Hilf G, Glerschik P, and Jakobs KH (1989) Muscarinic acetylcholine receptor-stimulated binding of guanosine 5′-O-(3-thiotriphosphate) to guanine-nucleotide-binding proteins in cardiac membranes. Eur J Biochem 186:725-731.
15. Ishida T, Oguri K, and Yoshimura H (1982) A novel metabolite of oxycodone in the urine of rabbits. J Pharmacobiodyn 5:134-136.
16. Jurna I, Komen W, Baldauf J, and Fleischer W (1997) Analgesia by dihydrocodeine is not due to formation of dihydromorphine: evidence from nociceptive activity in rat thalamus. J Pharmacol Exp Ther 281:1164-1170.
17. Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, and Goldenheim PD (1996) Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 59:52-61.
18. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
19. Kirkwood LC, Nation RL, and Somogyi AA (1997) Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. Br J Clin Pharmacol 44:549-555.
20. Lelas S, Wegert S, Otton SV, Sellers EM, and France CP (1999) Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. Drug Alcohol Depend 54:239-249.
21. Leow KP and Smith MT (1994) The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sci 54:1229-1236.
22. Loh HH, Liu HC, Cavalli A, Yang W, Chen YF, and Wei LN (1998) mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res 54:321-326.
23. Martin TJ, Kim SA, Cannon DG, Sizemore GM, Bian D, Porreca F, and Smith JE (2000) Antagonism of delta(2)-opioid receptors by naltrindole-5′ -isothiocyanate attenuates heroin self-administration but not antinociception in rats. J Pharmacol Exp Ther 294:975-982.
24. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, et al. (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature (Lond) 383:819-823.
25. Mignat C, Wille U, and Ziegler A (1995) Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci 56:793-799.
26. Mikus G, Somogyi AA, Bochner F, and Eichelbaum M (1991) Codeine O-demethylation: rat strain differences and the effects of inhibitors. Biochem Pharmacol 41:757-762.
27. Nitsche JF, Schuller AG, King MA, Zengh M, Pasternak GW, and Pintar JE (2002) Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci 22:10906-10913.
28. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, and Sellers EM (1993) CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 54:463-472.
29. Poyhia R, Seppala T, Olkkola KT, and Kalso E (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33:617-621.
30. Schmidt H, Vormfelde S, Klinder K, Gundert-Remy U, Gleiter CH, Skopp G, Aderjan R, and Fuhr U (2002) Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol 91:57-63.
31. 35S]GTPgammaS binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther 285:496-505.
32. Selley DE, Sim LJ, Xiao R, Liu Q, and Childers SR (1997) mu-Opioid receptor-stimulated guanosine-5′-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol 51:87-96.
33. Sim LJ, Selley DE, and Childers SR (1995) In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5′-[gamma-[35S]thio]-triphosphate binding. Proc Natl Acad Sci USA 92:7242-7246.
34. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, and Uhl GR (1997) Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94:1544-1549.
35. Speyer E and Sarre K (1924) Action of bromocyanogen on hydroxycodeinone and dihydrohydroxycodeinone. Chem Ber 57:1427-1430.
36. Szekeres PG and Traynor JR (1997) Delta opioid modulation of the binding of guanosine-5′-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. J Pharmacol Exp Ther 283:1276-1284.
37. Tomkins DM, Otton SV, Joharchi N, Li NY, Balster RF, Tyndale RF, and Sellers EM (1997) Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther 280:1374-1382.
38. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 47:848-854.
39. Weinstein SH and Gaylord JC (1979) Determination of oxycodone in plasma and identification of a major metabolite. J Pharm Sci 68:527-528.
40. Wilder-Smith CH, Hufschmid E, and Thormann W (1998) The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers. Br J Clin Pharmacol 45:575-581.
41. Yu A, Kneller BM, Rettie AE, and Haining RL (2002) Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10 and 2D6.17 allelic isoforms. J Pharmacol Exp Ther 303:1291-1300.